August 13, 2026
Overall Abundance Score: 79/100
Status: Up two points from last week’s 77. The steel breakthrough is real but early-stage. What moved the score was how much of this week’s news was already in effect: an approved drug, a launched hospital program, mini-grids being switched on, a battery fleet doing real grid work at peak hours.
Executive Summary
This week’s clearest story came out of Hong Kong, where engineers at the University of Hong Kong built a new stainless steel, called SS-H2, that resists corrosion well enough to replace the costly titanium components used in seawater hydrogen electrolyzers, at roughly one-fortieth the material cost. That is a real, peer-reviewed materials result, and it targets a genuine bottleneck: titanium is one of the largest cost drivers in producing hydrogen from seawater rather than purified fresh water, which most of the world does not have to spare. This does not make hydrogen cheap. It makes one expensive part of it less expensive.
The rest of the week filled in around that with expansion rather than invention. Tampa General Hospital launched Florida’s first newborn whole-genome screening program, testing for roughly 750 treatable genetic conditions instead of the usual 60. The FDA’s approval of Pluvicto as a first-line prostate cancer treatment took effect in clinics this week, nearly doubling the number of patients eligible for it. Kenya moved toward commissioning 120 new solar mini-grids under an existing off-grid access program, and Australia’s grid battery fleet set new records for how much of the country’s peak power it now supplies, displacing gas in the process. None of these are new technologies. All of them are existing tools reaching people or problems they did not reach a week ago.
None of this is finished. The steel is a lab result with no announced path to a commercial electrolyzer component yet. Tampa General’s program is a single-hospital pilot, not yet statewide, and genome sequencing in newborns still raises real questions about incidental findings and follow-up care that Florida has not fully answered. Pluvicto’s broader approval expands who can get the drug, not proof that starting earlier extends survival; that data is still maturing. Kenya’s mini-grids are being commissioned, not yet all commissioned, under a program that has slipped timelines before. Australia’s battery record is one very good day, not a permanent shift in how the grid is priced.
Most weeks this newsletter looks for something brand new. This week, the story was mostly about things that already existed getting to more people. That is a quieter kind of progress, and a real one.
Breakthrough of the Week
A cheaper steel could make seawater hydrogen 40 times less costly to build
What happened: Researchers led by Professor Mingxin Huang at the University of Hong Kong’s Department of Mechanical Engineering developed a new stainless steel, designated SS-H2, using a “sequential dual-passivation” process that builds two protective layers instead of one, letting the alloy withstand the harsh, corrosive conditions inside a seawater hydrogen electrolyzer. In testing, it performed comparably to the titanium components electrolyzers currently require, at roughly one-fortieth the structural material cost.
Why it matters: Titanium is one of the largest line items in building an electrolyzer that can run on seawater instead of purified fresh water, which most coastal and water-stressed regions cannot spare for industrial hydrogen production. A steel substitute that performs as well removes a major cost barrier to that entire category of hydrogen production, not just one product.
What friction it removes: Ordinary stainless steel corrodes too quickly in the acidic, oxygen-rich conditions of a working electrolyzer to be usable there, which is why the industry has relied on titanium despite its cost. SS-H2’s second protective layer is what lets ordinary steel survive conditions that would otherwise destroy it.
What to keep sober: This is a laboratory material, published in a peer-reviewed materials journal, not a commercial electrolyzer component. The researchers themselves note that turning it into real hardware, meshes, foams, and manufactured parts, still involves difficult engineering work with no announced timeline.
The abundance signal: A verified 40-fold cost reduction on a major line item, even for one component, is the kind of unglamorous fix that eventually shows up in a lower price for the hydrogen a coastal country can make from the ocean already next to it.
Source: ScienceDaily, August 11, 2026
Major Developments
1. Florida’s first newborn genome screening program goes live in Tampa
Tampa General Hospital began enrolling newborns on August 9 in Florida’s Sunshine Genetics Newborn Screening Program, becoming the first hospital in the state to offer free whole-genome sequencing to newborns as a voluntary pilot, screening for roughly 750 conditions rather than the standard 60 covered by conventional newborn blood-spot testing. The program was created by the Sunshine Genetics Act, legislation sponsored by state Rep. Adam Anderson after his son Andrew died of Tay-Sachs disease following more than a year of misdiagnosis.
Why it matters: Standard newborn screening catches a narrow band of treatable conditions. Whole-genome sequencing can catch hundreds more, many of them treatable if caught early and effectively untreatable once symptoms appear, exactly the gap that cost the bill’s sponsor his son.
What to keep sober: This is a single-hospital, voluntary pilot, not a statewide mandate, and broader genomic newborn screening raises real unresolved questions: incidental findings unrelated to the conditions being screened for, family anxiety over uncertain variants, and the capacity of the health system to follow up on every positive result. Success in Tampa does not guarantee a smooth statewide rollout.
The abundance signal: This is a program that started enrolling patients, not one that was proposed or funded. Free, state-backed genome sequencing for every newborn at a major hospital is a concrete expansion of what a birth in Florida now includes.
Source: Bay News 9, August 9, 2026
2. Australia’s grid batteries start outpricing gas at peak hours
Australia’s grid-scale battery fleet set multiple records on August 11, setting the wholesale price in 46 percent of the evening peak’s five-minute pricing intervals, overtaking gas as the dominant price-setter during that window for the first time. The fleet absorbed nearly 4 gigawatts of midday solar and discharged more than 4.3 gigawatts back into the grid that evening; national battery discharge rose 111 percent over the prior year’s record, with New South Wales discharge up 212 percent.
Why it matters: Batteries displacing gas as the price-setter at peak hours, even for one day, is a sign the technology has crossed from supplementing the grid to running a meaningful share of it during the hours that matter most for cost and emissions.
What to keep sober: This is a single, especially strong day, not a permanent shift, and it happened on a grid that has been adding battery capacity faster than almost anywhere else in the world; other grids without that build-out will not see the same numbers soon. Gas still sets prices in most other intervals.
The abundance signal: A grid demonstrably using stored solar power to outcompete gas on price at peak hours, even briefly, is evidence the economics are moving in a specific and checkable direction.
Source: IndexBox, August 11, 2026
3. Kenya moves to switch on 120 more solar mini-grids
Kenya is preparing to commission 120 solar mini-grids under the $150 million Kenya Off-Grid Solar Access Project, extending electricity to communities beyond the reach of the national grid, according to an August 12 roundup of African solar deployments. The same week, Eswatini launched a 10-megawatt solar plant and utility developer AMEA energized a 24-megawatt project elsewhere on the continent.
Why it matters: Mini-grids are how most of rural Africa is likely to get electricity before a national grid ever reaches it; each one commissioned is a specific community moving from no reliable power to some.
What to keep sober: KOSAP, the program funding Kenya’s mini-grids, has slipped its own timelines before, and “preparing to commission” is not the same as connected and running. Mini-grid economics also remain fragile in low-income, low-usage communities without continued subsidy.
The abundance signal: This is incremental, unglamorous, and exactly the kind of infrastructure expansion that does not make international headlines but shows up, community by community, in who has power and who does not.
Source: SolarQuarter, August 12, 2026
4. A cancer drug already on the market gets a much bigger patient pool
The FDA’s July 31 approval of Pluvicto (lutetium Lu 177 vipivotide tetraxetan) in combination with hormonal therapy as a first-line treatment for PSMA-positive metastatic prostate cancer took effect in clinics this week, nearly doubling the number of patients eligible for the drug. Previously, Pluvicto was only approved for patients whose cancer had already progressed despite hormonal treatment; the new approval lets PSMA-positive patients receive it from the start of treatment.
Why it matters: This is not a new drug. It is an existing, already-manufactured therapy reaching a much larger group of patients earlier in their disease, without waiting for new trials, new manufacturing capacity, or new pricing negotiations.
What to keep sober: This falls slightly outside this issue’s usual seven-day window — the approval was granted July 31 — but is included here because its practical impact, a nearly doubled eligible patient population gaining access to first-line treatment, is only now working through clinics. Broader eligibility is not the same as proof that starting Pluvicto earlier extends survival; that follow-up data is still being collected.
The abundance signal: Expanding who can access a therapy that already works is one of the most reliable, fastest ways to increase real-world abundance in medicine, faster than waiting for the next drug.
Source: FDA, July 31, 2026
Why This Matters
The connecting thread this week is reach, not invention. A steel alloy makes an existing hydrogen process reachable at a lower cost. A hospital makes genome-level screening reachable to Florida newborns. A drug makes first-line treatment reachable to nearly twice as many prostate cancer patients. Mini-grids make electricity reachable to Kenyan communities the national grid has not gotten to. A battery fleet makes stored solar power reachable at the exact hour gas used to own. None of these required a scientific breakthrough to happen this week; they required money, regulatory approval, construction, or enrollment — follow-through that is more mundane than discovery and, week to week, considerably more common.
Each still depends on follow-through that has not happened yet. The steel needs a manufacturer willing to build electrolyzer components out of it. Tampa’s pilot needs to prove it can respond responsibly to the incidental findings whole-genome sequencing will inevitably surface before it earns a statewide mandate. Kenya’s mini-grids need construction crews and financing to actually reach 120 commissioned sites, not just a plan for them. Pluvicto’s broader use needs survival data, not just eligibility, to justify itself as the new standard of care. And Australia’s one record evening needs many more like it before it is a trend rather than a headline.
Abundance Index Score
This week’s score: 79/100
Last week: 77/100
Change: +2
Why the score rose: More of this week’s evidence was already in effect rather than proposed. Regulatory approval, patient enrollment, and grid data are harder to walk back than a lab record or a memorandum of understanding, which is what carried most of last week’s score.
Why the score is not higher: The single most exciting result, the steel, is still a lab material with no path to production named yet, and every other story this week describes an existing system extending its reach rather than a new capability appearing. Extension is real progress, but it moves the number less than a genuine first does.
Score interpretation: A high-70s score means the week’s progress was solid, checkable, and spread across several unglamorous fronts, without a single story big enough to carry the number on its own.
Looking Ahead
Does SS-H2 steel reach an actual electrolyzer manufacturer, or stay a materials-journal result like many “40 times cheaper” claims before it?
Does Tampa General’s pilot handle its first incidental genetic findings well enough to support a statewide Sunshine Genetics rollout?
Do Kenya’s 120 mini-grids get connected on the timeline KOSAP has set, or slip again?
Does Australia’s battery fleet repeat its August 11 price-setting performance, or was that one unusually favorable day?
Does follow-up data show Pluvicto’s earlier use actually extends survival, or just delays the same outcome?
Closing Reflection
A steel resists what titanium once had to.
A newborn’s genome is read before a disease gets the chance to hide.
A drug already on shelves reaches a patient months earlier than it used to.
A village in Kenya gets a wire it did not have last week.
A battery in Australia outbids gas for one evening, and remembers how.
Nothing here is new. All of it goes further than it did seven days ago.
Source Notes and Fact-Check
SS-H2 stainless steel for seawater hydrogen electrolyzers: verified current, peer-reviewed in Materials Today, reported by ScienceDaily, August 11, 2026.
Tampa General Hospital Sunshine Genetics newborn whole-genome screening launch: verified current, Bay News 9, August 9, 2026.
Australia grid battery storage records for August 11: verified current, IndexBox, August 11, 2026.
Kenya 120 solar mini-grid commissioning and other African solar deployments: verified current, SolarQuarter, August 12, 2026.
Pluvicto first-line PSMA-positive metastatic prostate cancer approval: verified current, approved July 31, 2026, slightly outside this issue’s seven-day window but included because its practical patient impact is only now reaching clinics, FDA, July 31, 2026.